Q1 2026 · 13F-HR
Enavate Sciences GP, LLCholdings as filed
Filed 2026-05-15 · accession 0001953107-26-000008
$351.5M
Reported value
7
Positions
2026-03-31
Period end
The Brief · Enavate Sciences GP, LLC · Q1 2026
AI · grounded in 13F
Enavate Sciences GP, LLC reduced its position in CAMP by 27.83%. The fund also trimmed its holding in IMNM by 24.22%. These were the only changes to a portfolio consisting of 7 positions with total assets under management of $351.51M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 829401108 | SION | SIONNA THERAPEUTICS INC | $99.3M | 28.3% | 2,478,030 | Common | SOLE |
| 45257U108 | IMNM | IMMUNOME INC | $79.0M | 22.5% | 3,613,799 | Common | SOLE |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $76.6M | 21.8% | 3,919,159 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $41.2M | 11.7% | 7,788,150 | Common | SOLE |
| 107924102 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | $23.5M | 6.69% | 2,626,946 | Common | SOLE |
| 91678A107 | UPB | UPSTREAM BIO INC | $22.1M | 6.30% | 2,459,703 | Common | SOLE |
| 13463J101 | CAMP | CAMP4 THERAPEUTICS CORP | $9.7M | 2.75% | 2,190,920 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.